Delaere K P, Van Dieijen-Visser M P, Gijzen A H, Brombacher P J
Department of Urology, De Wever Hospital, Heerlen, The Netherlands.
Am J Clin Oncol. 1988;11 Suppl 2:S65-7. doi: 10.1097/00000421-198801102-00015.
Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) levels were determined in 241 patients attending the Department of Urology. The population consisted of 140 prostate cancer patients (34 newly diagnosed and 106 under treatment) and 101 patients with benign prostatic hypertrophy (BPH). The diagnostic values of PAP measured by enzymatic assay (EA) and by immunoenzymetric assay (IEMA) appeared to be similar. Elevated PAP (IEMA) levels were found in 10% of the patients with BPH and in 38% of the cancer patients. PSA was measured by immunoradiometric assay (IRMA) and receiver operating characteristic curves were constructed to compare the diagnostic benefits of different cutoff values. PSA (10 micrograms/L) reached a specificity of 88% and a sensitivity of 46%. With a cutoff value of 2.7 micrograms/L, the sensitivity increased to 64%, whereas the specificity fell to 58%. It is concluded that PSA is the most useful marker as a screening test.
对241名到泌尿外科就诊的患者测定了前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）水平。研究人群包括140例前列腺癌患者（34例新诊断患者和106例正在接受治疗的患者）以及101例良性前列腺增生（BPH）患者。通过酶促测定法（EA）和免疫酶测定法（IEMA）测得的PAP诊断价值似乎相似。在10%的BPH患者和38%的癌症患者中发现PAP（IEMA）水平升高。通过免疫放射测定法（IRMA）测量PSA，并构建受试者工作特征曲线以比较不同临界值的诊断效益。PSA（10微克/升）的特异性达到88%，敏感性为46%。临界值为2.7微克/升时，敏感性增至64%，而特异性降至58%。得出的结论是，PSA作为筛查检测是最有用的标志物。
